LSI Europe Summit Presenting Companies | Emerging Medtech Startups

Christopher Carlton

Chairman and CEO, Accure Acne

Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment.

Lucas Decuypere

CEO, Allegro

Our lead product is Hydrocelin, a first-in-class, minimally invasive injectable therapy, designed as a disease-modifying treatment for osteoarthritis. Hydrocelin is designed to address the primary cause of osteoarthritis: the loss of the rheopectic and viscoelastic characteristics of the synovial fluid. Once injected, Hydrocelin mixes with the synovial fluid, where it adapts under load to absorb and dissipate impact forces and replicate the mechanics of healthy joint fluid through resilient nanostructured crosslinking. This restores joint function and relieves pain, while initiating a mechanobiological cascade that protects and potentially regenerates cartilage. Hydrocelin does not suppress symptoms. It corrects the physics of the joint and changes the trajectory of the disease.

Sean Morris

President & CEO, Amplifi Vascular

Amplifi Vascular is developing the Amplifi™ Vein Dilation System, a proprietary blood pump technology designed to enlarge veins and improve outcomes for patients requiring arteriovenous fistula (AVF) surgery. The system is intended to increase AVF eligibility, accelerate maturation, reduce failure rates, and extend primary patency. By addressing key challenges in dialysis access, Amplifi aims to improve treatment outcomes for patients with end-stage renal disease.

Robert Kieval

President and Chief Executive Officer, Arctx Medical, Inc.

Arctx Medical, a clinical-stage medical technology company, is developing the world's first targeted treatment for Acute Pancreatitis (AP), and is introducing a superior new approach for patient temperature management. Targeted cooling is a well-established therapy for treating acute inflammatory conditions within the body. The Arctx Cool Catheter™ (ACC) Set delivers minimally invasive, selective, and potent cooling therapy to the pancreas, intended to reduce inflammation, accelerate patient recovery, and prevent more serious complications including organ failure and death. Arctx is embarking on an IDE-approved US pivotal clinical trial for this first-ever dedicated treatment for AP. In addition, Arctx now has FDA clearance for the ACC for patient temperature management, a second and mature market for its technology in which it is beginning to commercialize.

Karen Noblett

CEO, AVeta Medical

AVeta Medical’s mission is to treat the underlying cause of genitourinary syndrome of menopause without side effects.

Enrique Vega

CEO, Azalea Vision

Azalea Vision is developing a solution for patients with conditions and disorders that increase sensitivity to light. The company's solution actively adapts and manages within a personalized contact lens. The lens will also be capable of compensating for refractive errors of the eye, such as astigmatism and myopia.

John Brumfield

CEO, Berlin Heals

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life.

Alexis Peyroles

CEO, BetaGlue Therapeutics SpA

BetaGlue Therapeutics is pioneering targeted nuclear therapies for solid tumours. YntraDose, our solution, is a combination of a biocompatible bioglue and Yttrium 90 microspheres, that is designed to transform pancreatic cancer treatment through localized, effective, and safe therapy.

Jeremy Wheeler

CEO, BIOCAPTIVA LTD

BIOCAPTIVA develops

Edouard Fonck

CEO, Cairdac

Cairdac is a French medtech company developing a new generation of leadless pacemakers powered by the heart itself, designed to eliminate the fundamental limitations of current cardiac pacing systems and redefine the standard of care. ALPS™ enables a fully self-powered, leadless pacemaker combining continuous monitoring, expanded pacing capabilities, and long-term autonomy. This approach allows Cairdac to overcome the key trade-offs that have so far limited the adoption of leadless technologies. The company is preparing its clinical studies

Paul Sargeant

President & Chief Executive Officer, Circular Genomics

Circular Genomics is a biotechnology company revolutionizing neurological and psychiatric precision medicine. The company provides a unique understanding of dynamic brain processes that will transform how neurological and psychiatric conditions are diagnosed and managed leveraging unique, brain-enriched circular RNA biomarkers via simple blood tests. These biomarkers serve as ideal neurological biomarkers. We are advancing tests in Alzheimer’s and Parkinson’s Disease.

Moises Barbera Ramos

Founder and CEO, CLARO Surgical

Claro Surgical is reinventing orthopedic surgeries with the latest in mixed reality and artificial intelligence via the only FDA-registered platform: OrthoMR.

Yana Reshetnyak

CEO, CleanMargin

CleanMargin is a clinical-stage company developing the proprietary fluorescent surgical imaging agent, MarginVue, that enables surgeons to precisely visualize and remove all cancer lesions during breast-conserving cancer surgeries to achieve clean (cancer-free) surgical margins, addressing a large unmet medical need in breast cancer and many other cancer surgeries. Our ongoing Phase II clinical trials conducted at Memorial Sloan Kettering Cancer Center together with our device partner, Stryker Corp., demonstrate that MarginVue is safe and detects all sub-types of breast cancer with 100% sensitivity

Regina Atim

Founder, Clinicians Touch ALLYVE

Clinicians Touch ALLYVE is developing a wearable maternal bracelet and corresponding application that collects patient-generated data during pregnancy. The device will empower tracking of key data that can be shared with providers to improve outcomes during pregnancy.

Jochen Reinöhl

CEO, Coramaze Technologies

Coramaze Technologies is developing an fast end effective solution for the treatment of tricuspid regurgitation. The TriPair system is deigned to be anchored atraumatically to the right atrium. The device is intended to be easily placed in a procedure taking less than twenty minutes, without the need for anesthesia or TEE. TriPair is agnostic of valve morphology and can be retrieved if necessary

Bertrand Moal

CEO, DESKi

HeartFocus is an FDA-cleared, AI-powered cardiac ultrasound platform designed to radically expand access to echocardiography. The software provides real-time acquisition guidance and automatic quality validation, enabling clinicians with minimal ultrasound training to consistently capture diagnostic-quality transthoracic echocardiographic views. By shifting image acquisition from scarce specialists to a broader clinical workforce — including nurses, PAs, and frontline providers - HeartFocus addresses a critical bottleneck in cardiac care across emergency medicine, primary care, and resource-limited environments.HeartFocus is FDA cleared and commercially available in the United States, with early customers live and active across multiple care settings - positioning the platform for rapid scale in preventive, acute, cardiac care, and educational institutions.

Solveig Johannessen

CEO, Dova Health Intelligence

Dova builds advanced AI solutions that empower clinicians and researchers with actionable insights to advance GI care.

Pri Hancock

CFO, Echopoint Medical

Echopoint Medical is developing the IKOR™ coronary physiology system, an advanced optical sensor technology that measures coronary microvascular function in real time during routine cath lab procedures. By enabling accurate diagnosis of coronary flow, pressure & temperature, syndromes like ischaemia with non-obstructive coronary arteries (INOCA)—a condition that disproportionately affects women—IKOR helps physicians personalize treatment and reduce unnecessary stents and repeat procedures.

Veronique Ameye

CEO, ElectraDx

Patsnap empowers IP and R&D teams with advanced AI to get better answers and make faster decisions. Increase IP productivity by 75% while reducing R&D wastage by 25%.

Field Medical is developing a next-generation pulsed field ablation (PFA) solution for the treatment of cardiac arrhythmia. The company is building a purpose-built system that incorporates PFA, contact force sensing, electromagnetic localization, and artificial intelligence-enabled mapping capabilities to address the limitations of first-generation PFA technologies and deliver more efficacious therapy.

Dr. ir. Christoff Heunis

CEO, Flux Robotics B.V.

Flux Robotics develops a magnetic navigation platform for vascular interventions. The system uses external magnetic fields to steer guidewires and microcatheters through complex vascular anatomy, supporting more controlled and predictable navigation during procedures such as blocked artery crossing and complex stent placement.

Laura Becerra-Fajardo

CEO, FORESEE MedTech

FORESEE MedTech is a deep-tech spin-off awardee of the European Innovation Council (EIC) Transition grant (2.5 M€), that is developing an intravascular multiparametric sensing platform for remote monitoring of chronic conditions, starting with heart failure. FORESEE’s solution aims to support earlier interventions, reduce hospitalizations, empower patients and improve long-term outcomes in this cardiovascular condition. Thanks to the ability to measure multiple parameters from a single intravascular device, FORESEE will improve patient management by addressing the fact that in heart failure "one size does not fit all

Maurits Huigen

CEO, Gilbert

Gilbert (Eindhoven, The Netherlands) is a Dutch MedTech company revolutionizing inhaled therapeutics with precision delivery of next-gen therapies, with its next-gen Smart Precision Inhaler device. Gilbert's breakthrough scalable delivery platform offers the precision and adaptability modern inhaled therapies require - and the simplicity patients demand; a launchpad for next-gen therapies.

Raj Shah

CEO, GuideAI Health

GuideAI Health automates the early detection of chronic vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts. The platform's first product addresses the 90% underdiagnosis/misdiagnosis rate of peripheral vascular disease in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision.

Christopher Lee

Co-Founder & CEO, HapticHeart Solutions, Inc.

HapticHeart Solutions is advancing a wearable haptic feedback platform—featuring a glove and armband—that restores tactile sensation in catheter-based, minimally invasive, and robotic procedures. By converting physical and physiological signals into real-time touch and force feedback, the system aims to enhance surgical precision, shorten learning curves, and improve patient outcomes. Currently at Technology Readiness Level 6, the prototype has demonstrated clinical utility in electrophysiology and is being expanded for use in robotic surgery.

Francis White

CEO, Heart Biotech Ltd

The Yacoub Heart Valve: A unique, tissue-engineered valve that promises to revolutionise heart valve replacement with no compromises. Using intricate scaffold technology that transforms in-situ into a living heart valve, using the body's own healing processes to regenerate as nature intended. Restoring full life expectancy and in kids, adapting and growing.

Peter Fischer

CEO, Inkspace Imaging

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics.

Rubén Molina

CEO & Co-Founder, INNITIUS

Innitius has developed a quantitative diagnostic platform that measures cervical tissue biomechanics combined with AI models to support clinical decision-making in obstetrics. The technology addresses key use cases including threatened preterm labor, early preterm birth risk stratification, and induction of labor, enabling more accurate and objective assessment at the point of care.

Malin Nilsson

CEO, Inossia

Inossia is developing a platform technology focused on reducing repeat fractures in patients receiving bone cement for fracture repair. The company's lead product, V-Flex, is a bone cement for vertebral augmentation that hardens at a significantly lower temperature compared to competing bone cements. The soft cement is ideal for osteoporotic bones to adjacent fracture risk without compromising on mechanical support.

Nitzan Hirsh

Co-Founder and CEO, LuSeed Vascular

LuSeed's DOME is a minimally invasive device for treating bifurcation and sidewall brain aneurysms simply and effectively. The device utilizes a braided mesh design that makes it position-agnostic within the aneurysm. Another benefit of the DOME device is its design, which minimizes protrusion to the parent artery, thereby mitigating the need for dual anticoagulation therapy.

Gunter Trojandt

Managing Director, MDA - Medical Decision Alliance GmbH

MDA is building a best-in-class surgical reference database and translating the expertise of leading surgeons into advanced, AI-powered intra-operative decision-support solutions. Backed by €4 million in seed capital, MDA has successfully validated its business model over the past 24 months. To unlock the full potential of its approach and secure long-term market leadership, MDA is now seeking further growth capital. The company logo and the presenter's photo are attached to this mail

Christopher Gleason

President & CEO, Moximed

Moximed is a commercial-stage medical device company offering the MISHA Knee System, an FDA-authorized Implantable Shock Absorber designed to treat medial knee osteoarthritis. The device is placed on the inner side of the knee during an outpatient procedure to absorb the impact of walking, reducing joint force by 30%. Differentiated by its joint-preserving design that does not require cutting bone, Moximed bridges the gap between conservative therapies and total knee replacement, offering active patients superior pain relief and mobility.

George Kramer

Founder & CEO, NeoCor

NeoCor develops the CoApt Valve®, a transcatheter device designed to treat severe mitral and tricuspid valve disease through a minimally invasive approach. The CoApt Valve features a self-expanding nitinol frame and an electrospun polymeric valve, aiming to reduce or eliminate regurgitant jets without the need for open-heart surgery. The device is delivered via a catheter inserted through the transfemoral vein, preserving the native valve structure. CoApt Valve is advancing its technology through preclinical studies in both canine and human models, with plans to initiate veterinary clinical trials.

Ana Maiques

CEO & CoFounder, Neuroelectrics

Neuroelectrics unlocks the power of computational neuroscience to treat brain disorders—pioneering non-invasive tech for personalized neuromodulation, aiming to restore brain health & improve lives.

Lloyd Diamond

CEO, Nitinotes

Nitinotes Ltd. is an early commercial-stage medical device company advancing endoluminal innovation for obesity care. Its flagship platform, EndoZip™, is the first fully automated, single-operator suturing system designed specifically for endoscopic sleeve gastroplasty (ESG). EndoZip™ is engineered to improve procedural workflow, support consistency, and enhance scalability of ESG while keeping physicians in control of technique and outcomes. The company received CE Mark approval in November 2025 and has initiated focused European commercialization, including its first commercial case in Italy. In the United States, EndoZip™ is an investigational device, currently being evaluated in the pivotal EASE clinical trial. Nitinotes is positioned at the intersection of metabolic intervention, procedural innovation, and growing global demand for minimally invasive obesity solutions.

Oliver Piepenstock

CEO & Founder, Noah Labs

Noah Labs Vox eliminates the no. 1 cause of hospital admissions - congestive heart failure - 3 weeks before hospitalization by analyzing voice changes caused by fluid build-up in the lungs and vocal tract. Trained on the world's largest heart failure voice data set, the patented technology is being piloted at Mayo Clinic, UCSF and Charité Berlin.

Tore Victor Chrom Allerup

CEO, Nordstar Medical

Nordstar Medical has developed a patented single-handed deployment device: a novel peripheral nerve block catheter (PNBC) designed for insertion before or after surgery to deliver local anaesthetic directly to targeted nerves. Rooted in nearly two decades of clinical research, this technology represents the first opioid-free, high-usability solution for managing postsurgical pain. Addressing a $56.5 billion global postoperative pain market, Nordstar is focused on U.S. and European orthopedic and anesthesia departments to improve recovery and reduce hospital length of stay (LOS) costs.

Hamed Hanafi

CEO, NovaResp Technologies Inc

cMAP® is an AI-enabled PAP platform algorithm that predicts and prevents respiratory episodes before they occur. Its personalized approach delivers therapy at lower, more comfortable pressures — driving significantly better patient adherence.

Thomas Weindl

CEO & Co-Founder, OLI

OLI is a medical device company developing a platform for accessible, affordable kidney care. The company is building compact, low-cost systems to unlock clinical-quality hemodialysis and hemodiafiltration therapies for kidney failure patients from virtually anywhere.

Manios Dimitrakakis

CEO, Panda Surgical

Panda Surgical, a University College London spinout, is introducing the world's first robotics and AI platform for minimally invasive neurosurgery, offering surgeons enhanced dexterity and decision-support to make these operations safer, more effective, and more widely adopted.

Matt Angle

CEO & Founder, Paradromics

Paradromics is building the world's most capable and clinically viable brain-computer interface (BCI) platform. Its advanced neurotechnology captures brain activity at the highest resolution, individual neurons, enabling AI-powered treatments for motor impairment, chronic pain, addiction, depression, and other neurological conditions. The company's first clinical product, Connexus® BCI, is designed to restore speech and communication for people who are unable to speak due to debilitating motor conditions.

Marcel Both

CEO, PharmaSens AG

PharmaSens is developing a fully integrated, automated insulin delivery platform that combines an insulin pump, continuous glucose monitor (CGM), and control algorithm into a single wearable device. The system is purpose-built to overcome current adoption barriers and unlock access to the ~80% of insulin-dependent patients not using pumps today.

Christopher von Jako

CEO, Polarean

Visit our website to learn more.

Jannis Fischer

CEO, Positrigo

NeuroLF is a compact, dedicated brain PET imaging system designed to make high-quality neuroimaging more accessible and cost-effective. By combining advanced detector technology with a streamlined design, it enables earlier detection and monitoring of neurodegenerative diseases such as Alzheimer's Disesae in a wider range of clinical settings, including neurology offices.

Karl Stoklosa

CEO, Precisis

EASEE is an innovative, evidence-based neurostimulation platform that offers a fully reversible, less invasive alternative to traditional treatments, reducing risks and side effects. Its first application in epilepsy care uniquely combines two therapeutic strategies to provide a safe, effective option for patients who have not responded to conventional therapies.

Marcin Golebicki

CEO and Founder, ReNavie Sensing

ReNavie Sensing is the new novel technology focusing on mapping Renal Denervation and solving non responder issue.

Marc Zemel

CEO, Retia Medical

Retia develops healthtech AI algorithms for helping guide management of surgical and critically ill patients to improve outcomes. This is a $4 billion market. The company's technology has been clinically validated and is used in 65 hospitals.

Christos Bergeles

Founder and CEO, Revitalise

Revitalise develops a robotic microsurgical platform for ultra-precise retinal therapy delivery and for procedures beyond the reach of human dexterity. The platform is therapy-agnostic, aiming to be the delivery operating system for the next generation of retinal medicine, with a global market opportunity in the billions.

Will Mauldin

CEO, RIVANNA

RIVANNA® is a medical technology company developing clinical decision-support solutions powered by proprietary clinical datasets, AI models, and purpose-built imaging hardware. The company's platform automates complex anatomical analysis at the point of care, enabling faster, more confident clinical decisions while reducing variability and expanding access to advanced capabilities. The first applications target significant market opportunities in regional anesthesia and fracture care.

Maria Artunduaga

Founder & CEO, Samay

Samay’s Sylvee is the first wearable to match CT performance, the gold standard, for early COPD detection, identifying small airway disease up to 5 years before spirometry can detect any changes. Validated in 450+ patients (AUC 0.93) and protected by 18 patents across 20+ countries, Samay is already generating revenue with a top European respiratory pharma, a world-leading sleep company, and a top US academic medical center, while preparing for a late 2027 launch across 1,500 clinics through Latam’s third-largest payer and investor.

Berk Tas

CEO, SentiAR

Transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient.

Bart Bandy

Chief Executive Officer, Solenic Medical

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants.

Sanjay Kakkar

CEO, Tensive

Tensive is a clinical-stage biomaterials medical device company developing innovative bioresorbable scaffolds for breast reconstruction and tissue marking. Its patented REGENERA and SOFTAG scaffolds are designed to allow regeneration of the body's own tissue to create natural, safe and lasting reconstruction for patients recovering from lumpectomy or during cosmetic procedures. The result is restoration that preserves the original shape and feel of the patient's breast, yet is clearly differentiated from surrounding tissues on imaging.

Zeeshan Syedain

CEO, Vascudyne Inc

Vascudyne develops off-the-shelf bioengineered vascular and heart valve devices designed to regenerate into living cardiovascular tissues through host cell integration and remodeling. The platform targets major unmet needs in coronary, congenital, and structural heart disease by providing durable long-term solutions.

John Santini

President & CEO, Vergent Bioscience

Vergent’s lead compound, abenacianine for injection (VGT-309), is a next generation tumor-targeted fluorescent imaging agent for cancer surgery designed to provide real-time, intraoperative visual and molecular feedback on tumor location and help surgeons ensure all tumor tissue is removed during minimally invasive surgery (MIS) procedures. Abenacianine is designed to be an ideal targeted imaging agent and is compatible across NIR enabled surgical visualization platforms, works across all solid tumor types, and has a differentiated mechanism of action that allows for a wide dosing window to seamlessly fit into surgery workflows.

Finbar Dolan

CEO, VERSONO Medical

Versono is developing an intravascular ultrasonic platform to improve the crossing of severe occlusions in the peripheral vasculature. The device will prepare a working lumen to support endovascular therapy in patients with chronic total occlusions (CTOs) and critical limb ischemia (CLI).

Tushar Sharma, PhD

CEO & Founder, Vivifi Medical Inc

Vivifi Medical is pioneering the first non-surgical, non-urethral device for treating BPH that targets the hormonal root cause rather than simply managing symptoms. By redirecting testosterone-rich blood away from the prostate, our approach results in true regression without implants, urethral instrumentation, or compromise to sexual function.

Menachem Genut

Co-Founder & Chief Scientific Officer, YOPI

YOPI has developed a proprietary wearable device, worn on the upper arm, that continuously analyzes sweat to monitor key physiological electrolytes and metabolic markers in real time. The technology enables early identification of cardiovascular risk indicators—well before clinical symptoms appear, while delivering advanced performance insights, including real-time oxygen consumption (VO₂), accurate calorie expenditure, and substrate utilization (fat, carbohydrates, and proteins), along with additional critical physiological metrics. This non-invasive platform replaces traditional offline VO₂ testing and intermittent blood-based diagnostics with continuous, real-time, and clinically relevant health monitoring—effectively bringing the metabolic lab into everyday life.